News
Protein Sciences Corporation News
Web Site:
http://www.proteinsciences.com
- Sanofi Pasteur Inc.
1000 Research Pkwy.,
Meriden, CT 06450
- 7159
Tel: (203) 686-0800
Fax: (203) 686-0268
Protein Sciences Corporation, founded in 1983, is a privately held vaccine company with headquarters in Meriden, Connecticut. PSC's mission is to save lives and improve health.
View all News Articles for Protein Sciences Corporation
New England Journal of Medicine Publishes FluBlok � is Better
June 26, 2017
Meriden, CT �Protein Sciences Corporation announced the publication of clinical trial results comparing Flublok� Quadrivalent � the quadrivalent version of Flublok� influenza vaccine � to a traditional egg-based quadrivalent inactivated vaccine. The data published in the June 22nd issue of the New England Journal of Medicine showed that Flublok Quadrivalent provided significantly improved protection against laboratory confirmed influenza illness in older adults.The publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine. People who were given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza. This data satisfies both pre-specified criteria for noninferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine. Flublok Quadrivalent was approved by the FDA in October 2016 and will be available nationwide in prefilled syringes for the upcoming flu season.
"This study shows that Flublok� Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology." said Lisa Dunkle MD, Chief Medical Officer of Protein Sciences. "We demonstrated statistically significantly better protection by Flublok based on considerably fewer people contracting the flu after vaccination with Flublok Quadrivalent. Today, we announce that these peer-reviewed results have been published in the highly respected New England Journal of Medicine. Furthermore, physicians are eligible for up to 1 hour AMA PRA category 1 CME credit for reading the article. Clearly, Flublok represents a major step forward in combating influenza on a global scale."
For the complete technical article visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1608862
Member News is provided as a service of the Midstate Chamber of Commerce and is also featured in the monthly "Chamber News" newsletter mailed to members.
The “original publication date” of Member News articles posted on this web site reflects the date this article was added to the Chamber database and may not necessarily reflect the date such news events occurred.